On April 8, 2016 results from a recent clinical trial show that adjuvant therapy with sunitinib (Sutent®) or sorafenib (Nexavar®) does not improve progression-free survival for patients with renal cell (kidney) cancer and may cause serious side effects.
Both sunitinib and sorafenib target proteins on cancer cells that promote tumor angiogenesis—the formation of new blood vessels that are needed to fuel tumor growth beyond a certain size. Read more here.
No comments:
Post a Comment